Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8416 to 8430 of 8887 results

  1. Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270

    Discontinued Reference number: GID-TA10211

    Technology appraisal guidance
    Discontinued

  2. Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]

    Discontinued Reference number: GID-TA11252

    Technology appraisal guidance
    Discontinued

  3. Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]

    Discontinued Reference number: GID-TA11109

    Technology appraisal guidance
    Discontinued

  4. Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]

    In development Reference number: GID-TA11808 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]

    In development Reference number: GID-TA11848 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

    Discontinued Reference number: GID-DT14

    Diagnostics guidance
    Discontinued

  7. Community nursing care settings

    Discontinued Reference number: GID-SGWAVE0700

    Safe staffing guideline
    Discontinued

  8. Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]

    In development Reference number: GID-TA11441 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]

    In development Reference number: GID-TA11585 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]

    In development Reference number: GID-TA11368 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]

    In development Reference number: GID-TA11663 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

    Discontinued Reference number: GID-MT516

    Medical technologies guidance
    Discontinued

  13. Lung transplantation with ex-vivo perfusion

    Discontinued Reference number: GID-IP1046

    Interventional procedures guidance
    Discontinued

  14. Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]

    Discontinued Reference number: GID-TAG416

    Technology appraisal guidance
    Discontinued

  15. Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]

    Discontinued Reference number: GID-TAG278

    Technology appraisal guidance
    Discontinued